Cleveland, OH – According to filings with the U.S. Securities and Exchange Commission, Diasome Pharmaceuticals is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Geho played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Diasome Pharmaceuticals

Diasome is developing hepatocyte directed vesicle (HDV) technology to reduce the incidence of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. HDV technology is being developed as an additive to all forms of insulin to improve its safety and efficacy by restoring the liver’s natural role in blood glucose control. Diasome Pharmaceuticals, Inc. is developing an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. HDV may improve the safety and efficacy of any commercially available insulin by restoring the liver’s natural role in blood glucose control.

To learn more about Diasome Pharmaceuticals, visit http://diasome.com/

Contact:
Robert Geho, Chief Executive Officer
216-444-7110
https://www.linkedin.com/in/robert-geho-106a755/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved